Sun Pharma and Moebius Medical Collaborate on Osteoarthritis Treatment
Sun Pharmaceutical Industries Limited and Moebius Medical Limited are excited to share that the FDA has granted Fast Track designation to their innovative treatment, MM-II, which is designed to relieve knee pain caused by osteoarthritis. This designation plays a crucial role in facilitating the swift development and review of new therapies, especially those addressing significant medical needs.
What is Fast Track Designation?
The FDA's Fast Track program is essential for expediting the development of drugs aimed at serious medical conditions. This designation not only serves as recognition but also provides tangible benefits to the companies involved. One key advantage is the opportunity for more frequent communication with the FDA during the clinical development phase, which can help accelerate the approval process and enable patients to access new treatments more quickly.
Insights from Company Leaders
Dr. Marek Honczarenko, Senior Vice President at Sun Pharma, expressed his enthusiasm about the Fast Track designation, highlighting the potential of MM-II and the critical need for effective treatments for osteoarthritis. Moshe Weinstein, CEO of Moebius Medical, noted that this achievement follows encouraging Phase 2b data, suggesting that MM-II could provide effective and long-lasting relief from knee pain associated with osteoarthritis.
A Closer Look at MM-II
MM-II represents a significant advancement in pain management, utilizing a distinctive formulation of large, empty, multilamellar liposomes that aim to reduce joint friction and alleviate pain. Clinical trials have demonstrated that a single injection of MM-II can deliver substantial pain relief for up to 26 weeks, offering a promising alternative to traditional treatments that often involve opioids.
Exploring the Clinical Trial Landscape
The encouraging outcomes from clinical studies, particularly those presented at EULAR 2024, reinforce confidence in the effectiveness of MM-II. Both Sun Pharma and Moebius Medical are gearing up to launch a Phase 3 clinical program and are actively pursuing a CE Mark for MM-II across the European Union.
The Burden of Osteoarthritis
Osteoarthritis (OA) is a common condition marked by the degeneration of joint cartilage and surrounding tissues. This chronic disease affects millions of people worldwide, with estimates indicating over 100 million cases globally and more than 30 million in the United States alone. Symptoms typically include ongoing pain and reduced mobility, which can significantly diminish patients' quality of life and productivity.
Our Dedication to Innovation
Sun Pharma is a leader in the specialty generics market, offering a range of innovative medications. Their global specialty segment focuses on niche therapeutic areas, ensuring the availability of high-quality, accessible treatments in over 100 countries. With a diverse and skilled workforce, Sun Pharma is committed to developing therapies that improve patient care.
Moebius Medical's Collaborative Initiatives
Founded within the RAD Biomed Accelerator, Moebius Medical is dedicated to creating cutting-edge pain relief solutions for osteoarthritis. Their partnership with Sun Pharma enhances their ability to leverage resources and expertise necessary for advancing MM-II through the intricate process of drug development.
Contact Information
For media inquiries:
Gaurav Chugh
Tel Direct: +91 22 4324 5373
Mobile: +91 98104 71414
For investor relations:
Dr. Abhishek Sharma
Tel Direct: +91 22 4324 2929
Mobile: +91 98196 86016
Frequently Asked Questions
What is MM-II?
MM-II is a novel, non-opioid treatment developed to alleviate knee pain associated with osteoarthritis through a proprietary formulation using large liposomes.
What does Fast Track designation mean?
Fast Track designation facilitates and accelerates the development and review process of therapies intended for serious conditions like osteoarthritis, allowing for quicker patient access to treatments.
What benefits does MM-II offer over traditional treatments?
MM-II provides a non-opioid alternative for pain relief, which may reduce the risk of dependency associated with traditional pain medications.
Who has developed MM-II?
MM-II is jointly developed by Sun Pharmaceutical Industries and Moebius Medical, combining their expertise to address the significant need for effective osteoarthritis treatments.
What is the next step for MM-II?
The next phase includes initiating a Phase 3 clinical study to confirm the efficacy of MM-II and seeking necessary approvals for its use in broader markets.
